Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
An4.0
Aniracetam – Forschung
Überwiegend Mechanismus / Beobachtung
9 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Aniracetam sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2007–2018 mit einer typischen Studiengröße von 88 Teilnehmenden.
Basierend auf 9 Studien · 1 Meta-Analyse · 5 RCTs · 45,513 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
2geholfen· 7 weitere ohne bewertete Effektdaten
Nach Outcome
Cognitive functionFördert die Gedächtniskonsolidierung durch Modulation der AMPA-Rezeptoren · 2-4 weeks
Überwiegend Mechanismus / Beobachtung9 Studien
Neuroprotection & brain aging
Überwiegend Mechanismus / Beobachtung6 Studien
Anxiety & stressReduzierte Angst und verbesserte Stimmungsstabilität · 1-2 weeks
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 8 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
46k
typische Studie: 88 Personen
Stärkste Designs
6
1 gepoolt, 5 randomisiert
Zeigte Nutzen
100%
2/2 Studien
Wie lange Studien liefen
3+ Monate
1
Untersuchte Populationen
Dementia patients2
Senile patients with mild cognitive impairment2
Mild cognitive impairment patients1
Vascular dementia patients1
Ältere Forschungsbasis
Neueste Studie von 2018 · Neueste Meta-Analyse: 2018
200720122018
1Cognitive dysfunction in dementiaMeta-AnalyseCited 43×n=44,854 · very large study2018
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Perng CH et al. · Psychopharmacology (2018)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
Subgroup 1 drugs include piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam, which have been used in humans and some of which are available as dietary supplements.
Malykh AG, Sadaie MR · Drugs (2010)
Of the subgroup 1 racetams, oxiracetam and aniracetam are no longer in clinical use.
The modes of action of piracetam and most of its derivatives remain an enigma; differential effects on subtypes of glutamate receptors, but not the GABAergic actions, have been implicated.
Based on calculations of the efficacy rates, our assessments indicate notable improvements in clinical outcomes with some of these agents.
3Mild cognitive impairmentRCTCited 6×n=166 · medium study2007
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Zhong J et al. · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Shenwu gelatin capsule has certain effects on mild cognitive impairment.
Further research warranted to confirm findings
4Cognitive behavior ability in vascular dementiaRCTCited 9×n=88 · small study2014
The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets.
Li SK et al. · Zhongguo zhen jiu = Chinese acupuncture & moxibustion (2014)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
The total effective rate was 90.334 (28/31) in the combined therapy group, which was superior to 85.734 (24/28) in the body acupuncture group and 79.3% (23/29) in the western medication group (both P < 0.05).
The scalp acupuncture combined with auricular point sticking could improve the clinical symptoms and cognitive behavior ability in patients with vascular dementia, which has superior total efficacy to body acupuncture and western medication aniracetam tablets.
Further research warranted to confirm findings
5Clinical memory scale scoresRCTCited 12×n=45 · small study2008
Huannao Yicong capsule has better therapeutic effect than aniracetam capsule in treating senile mild cognitive impairment.
Li H et al. · Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine (2008)
Likely real
Other index scores of clinical memory scale and traditional Chinese medicine syndrome in patients of Huannao Yicong capsule-treated group were significantly improved as compared with those of the aniracetam-treated group (P<0.05, P<0.01).
Huannao Yicong capsule could significantly increase the activity of serum SOD and decrease the content of AchE, IL-1alpha and IL-6 (P<0.01, P<0.05), better than aniracetam.
Furthermore, Huannao Yicong capsule could significantly improve the blood lipid, such as the level of TG, LDL-C, HDL-C, ApoA-1 and ApoB-100 (P<0.01, P<0.05), and better than aniracetam (P<0.01, P<0.05).
6Mild cognitive impairment symptomsRCTCited 7×n=64 · small study2010
For treatment of MCI, HWD shows effects in improving patients' symptoms, cognition capacity and elevating serum Ach content better than that of Aniracetam; and with effects for raising SOD activity and reducing MDA level similar to those of Aniracetam.
Guo RZ et al. · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine (2010)
For treatment of MCI, HWD shows effects in improving patients' symptoms, cognition capacity and elevating serum Ach content better than that of Aniracetam; and with effects for raising SOD activity and reducing MDA level similar to those of Aniracetam.
Further research warranted to confirm findings
7Bioequivalence of aniracetam formulationsRCTn=20 · very small study2008
Therefore, the aniracetam test formulation can be regarded as bioequivalent to the aniracetam reference formulation.
Tian Y et al. · Arzneimittel-Forschung (2008)
The 90% confidence limits calculated for AUC and Cmax of aniracetam were within the standard bioequivalence range (80%-125% for AUC and Cmax).
AUC(0-2.5) values were 4.53 +/- 6.62 and 4.76 +/- 6.65 ng h/mL, the areas under the plasma concentration-time curve (AUC(0-infinity) were 4.62 +/- 6.66 and 4.85 +/- 6.71 ng h/mL for the test and reference formulation, respectively.
No statistical differences were observed for Cmax, and AUC(0-infinity) for aniracetam.
8Cognitive impairmentBeobachtungsstudieCited 16×n=276 · medium study2012
Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
Koliaki CC et al. · CNS neuroscience & therapeutics (2012)
In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
Our findings indicate that aniracetam (a nootropic compound with glutamatergic activity and neuroprotective potential) is a promising option for patients with cognitive deficit of mild severity.
It preserved all neuropsychological parameters for at least 12 months, and seemed to exert a favorable effect on emotional stability of demented patients.
Despite several studies demonstrating efficacy in impaired subjects, our findings suggest that aniracetam does not alter behavior in normal healthy mice.
Elston TW et al. · PLoS One (2014)
Daily 50 mg/kg oral aniracetam was tested across spatial learning, associative learning, motor learning, odor discrimination, locomotion, and anxiety measures in naive C57BL/6J mice.
We detected no significant differences between the naive, placebo, and experimental groups across all measures.
Despite several studies demonstrating efficacy in impaired subjects, our findings suggest that aniracetam does not alter behavior in normal healthy mice.